MTHFD2L

Across TCGA pan-cancer cohorts, MTHFD2L RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MTHFD2L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MTHFD2L RNA is repressed in tumor relative to normal tissue. In most cancer types MTHFD2L is over-expressed in tumor, although a few such as KIRC and LIHC show the opposite, repressed pattern.

KIRC, LIHC, and HNSC are the cancer types where MTHFD2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTHFD2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.835	<.001	11	view →
LIHC	Female	II,III,IV	−0.894	<.001	8	view →
HNSC	Male	III,IV	+0.589	<.001	8	view →
KICH	Female	All	−1.005	<.001	7	view →
UCEC	All	All	+0.693	<.001	6	view →
KIRP	Male	All	−0.586	<.001	4	view →
BRCA	Female	All	−0.212	.007	4	view →
BLCA	All	All	+0.309	.022	3	view →
PRAD	All	All	+0.522	<.001	2	view →
STAD	All	II,III,IV	+0.414	.013	2	view →
COAD	All	II,III,IV	+0.306	.018	2	view →
THCA	Male	IV	−0.450	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MTHFD2L–KIRC

Open the KIRC breakdown →